Adherence to adjuvant endocrine therapy including GnRH-analogues and survival: a population-based cohort study.

ABSTRACT:

Background

Adjuvant endocrine therapy (AET) combining gonadotropin-releasing hormone analogues (GnRHa) with tamoxifen (TAM) or aromatase inhibitors (AI) improves survival in premenopausal women with breast cancer compared to TAM and is increasingly prescribed. However, there are concerns regarding adherence.

Methods

Through linkages to Swedish national healthcare registers, we conducted a population-based cohort study including women diagnosed with early, invasive, estrogen receptor-positive breast cancer, January 2007 to December 2020, in the Stockholm-Gotland region, Sweden, with at least one dispensation of oral AET (n = 16,468). Follow-up ended January 14, 2022.AET was categorized based on the first dispensed oral AET (AI or TAM) and if GnRHa had been dispensed within th

SUBMITTER: Eriksson Bergman L 

PROVIDER: S-EPMC12572808 | biostudies-literature | 2025 Oct

REPOSITORIES: biostudies-literature